

551697

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number
WO 2004/087948 A1

(51) International Patent Classification⁷: C12Q 1/68,
C07H 21/04, A61P 25/18

(21) International Application Number:
PCT/CN2004/000287

(22) International Filing Date: 31 March 2004 (31.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2,423,327 2 April 2003 (02.04.2003) CA

(71) Applicant (for all designated States except US): PHARMACO GENETICS LIMITED [CN/CN]; Rm. 3633, Annex Building, HKUST, Clear Water Bay, Kowloon, Hong Kong (CN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): XUE, Hong [CN/CN]; 1/F. 24 Tsam Chuk Wan, Sai Kung, N. T., Hong Kong (CN). LO, Wing, Sze [CN/CN]; Rm. 3633, Annex Building, HKUST, Clear Water Bay, Kowloon, Hong Kong (CN).

(74) Agent: KANGXIN & PARTNERS; Suite 2516, Xinlong Mansion, A33 Erlonglu, Xicheng District, Beijing 100032 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/087948 A1

(54) Title: SINGLE NUCLEOTIDE POLYMORPHISMS FOR THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA SPECTRUM DISORDERS

(57) Abstract: Six single nucleotide polymorphisms (SNPs) are found to be associated with schizophrenia. The applications of these SNPs, and genetic markers in the same haplotype as, or linkage disequilibrium with, one or more of these six SNPs to diagnostic and drug development purposes are described in the present invention.

DESCRIPTION

SINGLE NUCLEOTIDE POLYMORPHISMS FOR THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA SPECTRUM DISORDERS

FIELD OF THE INVENTION

[0001] This invention relates to the diagnosis and treatment for psychotic and affective disorders, such as schizophrenia. This invention also relates to methods of screening for therapeutics for schizophrenia and other psychotic and affective disorders.

DESCRIPTION OF THE PRIOR ART

[0002] Common human neuropsychiatric disorders including psychotic and affective disorders are multi-factorial or complex in nature. The family of disorders that share clinical and often etiologic (i.e., genetic) characteristics with schizophrenia have been referred to as the "schizophrenia spectrum", which covers schizophrenia, nonschizophrenic, nonaffective psychotic disorders (i.e., schizophreniform disorder, delusional disorder, schizoaffective disorder, atypical psychosis), schizophrenia-like personality disorders and some affective disorders (A. Breier, 1999. Diagnostic classification of the psychoses: historical context and implications for neurobiology. In: Neurobiology of Mental Illness. D. S. Charney, E. J. Nestler, B. S. Bunney (Ed.) Oxford University Press. Chapter 15. pp. 197 – 198). To date, linkage studies have been relatively unsuccessful in identifying genes associated with complex disorders such as bipolar disorder, schizophrenia, depression, anxiety-related traits and autism; few loci have yet been unequivocally identified.

[0003] Schizophrenia is one of the most common and serious psychiatric disorders and is characterised by a profound disruption of cognition and emotion, affecting fundamental human attributes such as language, thought, perception, and sense of self. The disease is accompanied by an array of symptoms which frequently include hallucination and delusion. Studies of the prevalence of schizophrenia in the general population demonstrated that, in general, 1-year prevalence in adults between the ages of 18 to 54 is estimated to be 1.3 percent. Onset generally occurs during young adulthood (mid-20s for men, late-20s for women), although earlier and later onsets do occur. Onset of the disease may be abrupt or gradual, but most people experience some early signs, such as increasing social withdrawal, loss of interest, unusual behavior, or decreases in functioning prior to the beginning of active positive symptoms.

[0004] At this time, a clear consensus as to the etiopathogenesis of schizophrenia has yet to be established. The most popularly held opinion points to the interaction of genetic factors and major

environmental upheaval during development of the brain. Family, twin, and adoption studies support the role of genetic influences in schizophrenia (Kendler KS and Diehl SR, 1993. The genetics of schizophrenia: a current, genetic-epidemiologic perspective. *Schizophr Bull* 19:261-85; McGuffin P, Owen MJ and Farmer AE, 1995. Genetic basis of schizophrenia. *Lancet* 346: 678-82; Portin P and Alanen YO, 1997. A critical review of genetic studies of schizophrenia. II. Molecular genetic studies. *Acta Psychiatr Scand* 95:73-80). Immediate biological relatives of people with schizophrenia have about a 10-time greater risk than that of the general population. Given prevalence estimates, this translates into a 5 to 10 percent lifetime risk for first-degree relatives (including children and siblings) and suggests a substantial genetic component to schizophrenia (Kety SS, 1987. The significance of genetic factors in the etiology of schizophrenia: results from the national study of adoptees in Denmark. *J Psychiatr Res* 21:423-9; Tsuang MT, 1991. Morbidity risks of schizophrenia and affective disorders among first-degree relatives of patients with schizoaffective disorders. *Br J Psychiatry* 158:165-70). What also bolsters a genetic role are findings that the identical twin of a person with schizophrenia is at greater risk than a sibling or fraternal twin, and that adoptive relatives do not share the increased risk of biological relatives. However, in about 40 percent of identical twins in which one is diagnosed with schizophrenia, the other never meets the diagnostic criteria. The discordance among identical twins clearly indicates that environmental factors likely also play a role. However, despite the evidence for genetic vulnerability to schizophrenia, scientists are only beginning to identify the genes responsible (Kendler KS & Diehl SR, 1993. The genetics of schizophrenia: a current, genetic-epidemiologic perspective. *Schizophr Bull* 19:261-85; Shifman S, Bronstein M, Sternfeld M *et al.*, 2002. A highly significant association between a COMT haplotype and schizophrenia. *Am J Hum Genet* 71: 1296-1302). The current consensus is that multiple genes are responsible (Kendler KS, MacLean CJ, O'Neill FA *et al.*, 1996. Evidence for a schizophrenia vulnerability locus on chromosome 8p in the Irish Study of High-Density Schizophrenia Families. *Am J Psychiatry* 153:1534-40; Kunugi H, Curtis D, Vallada HP *et al.*, 1996. A linkage study of schizophrenia with DNA markers from chromosome 8p21-p22 in 25 multiplex families. *Schizophr Res* 22:61-8; Portin P and Alanen YO, 1997. A critical review of genetic studies of schizophrenia. II. Molecular genetic studies. *Acta Psychiatry Scand* 95:73-80; Straub RE, MacLean CJ, Martin RB, Ma Y, *et al.*, 1998. A schizophrenia locus may be located in region 10p15-p11. *Am J Med Genet* 81:296-301).

[0005] Excessive levels of the neurotransmitter dopamine have long been implicated in schizophrenia, although it is unclear whether the excess is a primary cause of schizophrenia or the result of a more fundamental dysfunction. Recent evidence implicates much greater complexity in the dysregulation of dopamine and other neurotransmitter systems (Grace AA, 1991. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. *Neuroscience* 41:1-24; Grace AA, 1992. The depolarization block hypothesis

of neuroleptic action: implications for the etiology and treatment of schizophrenia. *J Neural Transm Suppl* 36:91-131; Olie JP and Bayle FJ, 1997. New chemotherapy approaches to psychoses. *Encephal Spec* 2: 2-9). Some of this research ties schizophrenia to certain variations in dopamine receptors (Nakamura K, 1995. Symptomatologic characteristics and psychopathology of expression of an "attack of altered perception" in schizophrenic patients. *Seishin Shinkeigaku Zasshi* 97:529-50; Serretti A, Macciardi F & Smeraldi E, 1998. Dopamine receptor D2 Ser/Cys311 variant associated with disorganized symptomatology of schizophrenia. *Schizophr Res* 34:207-10), while other research focuses on the serotonin system (Inayama Y, Yoneda H, Sakai T, *et al.*, 1996. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. *Am J Med Genet* 67:103-5).

[0006] Serotonin is a key neurotransmitter in the central nervous system, and dysregulation of serotonergic pathways has been implicated in the pathogenesis of many complex psychiatric diseases. Polymorphisms of many of the genes involved in serotonin biosynthesis, catabolism, and response have been reported, suggesting that genetic variability may underlie the development of diseases such as schizophrenia, obsessive compulsive disorder, and suicide.

[0007] GABA (γ -aminobutyric acid) is a major neurotransmitter that mediates inhibitory transmission. GABA receptors are divided into two types, GABA_A receptors and GABA_B receptors. GABA_A receptors are the major inhibitory neurotransmitter receptors. They are ligand-gated chloride ion channels that possess binding sites for many important drugs thought to act, in part, through modulation of receptor function (Burt DR and Kamatchi GL, 1991. GABA_A receptor subtypes: from pharmacology to molecular biology. *FASEB* 5: 2916-2923).

[0008] Abnormalities of the GABA system have been implicated in the pathophysiology of schizophrenia (Adel A *et al.*, 1999. Critical review of GABAergic drugs in the treatment of schizophrenia. *J Clin Psychopharmacol* 19: 222-232). Several studies have also shown that in cortical GABA_A receptors, tritiated muscimol binding and levels of α , β_2 and β_3 subunits of the receptor increased. Moreover, the expression of the short isoform of the γ_2 subunit of this receptor may be markedly reduced in the dorsolateral prefrontal cortex (PFC) of schizophrenic subjects (Lewis DA, 2000. GABAergic local circuit neurons & prefrontal cortical dysfunction in schizophrenia. *Brain Research Reviews* 31: 270-276).

[0009] GABA_A receptors contain at least 18 subunits. They are located on the human chromosomes 1, 4, 5, 6, 15 and X. The α , $\beta_{2,3}$ and γ subunit genes of GABA_A receptor are genes that could be related to schizophrenia (Adel A *et al.*, 1999. Critical review of GABAergic drugs in the treatment of schizophrenia. *J Clin Psychopharm* 19: 222-232; Lewis DA, 2000. GABAergic local circuit neurons & prefrontal cortical dysfunction in schizophrenia. *Brain Research Reviews* 31: 270-276; Rapadimitrion G *et al.*, 2001.

Association between GABA_A receptor α_5 subunit gene locus and schizophrenia of a later age of onset.

Neuropsychobiology 43: 141-144)

[0010] The α_1 subunit is present predominantly in the cerebellum whereas the α_5 subunit is prevalent in the hippocampus, and α_6 subunit is expressed almost exclusively within the cerebellar granule cell. The α_4 subunit constitutes a more minor receptor subtype is expressed primarily in the thalamus and the hippocampus (Mehta AK, Maharaj KT, 1999. An update on GABA_A receptors. *Brain Res Rev* 29: 196-217).

[0011] The β subunit is a key structural and functional component of GABA_A receptors. It was recognized as a potential binding site for GABA (Krishek BJ *et al.*, 1996. Homomeric β_1 γ -aminobutyric acid_A receptor-ion channels: evaluation of pharmacological and physiological properties. *Molecular Pharmacology* 49: 494-504). The importance of β subunit isoforms in governing GABA_A receptor α_1 subunit expression has been suggested (Kumar M *et al.*, 2001. Antisense suppression of GABA_A receptor β_5 subunit levels in cultured cerebellar granule neurons demonstrates their importance in receptor expression. *J Neurochem* 77: 211-219). The most prevalent β subunit is β_2 , which was most often associated with the α_1 subunit (Stephenson FA, 1995. The GABA_A receptors. *Biochem J* 310: 1-9). The β_2 subunit has two isoforms: long form β_{2L} and short form β_{2S} . The h β_{2L} cDNA sequence is identical to h β_{2S} except for a 114 base pair (38 amino acids) insertion within the large intracellular loop between transmembrane regions III and IV. This 114 base pair insertion sequence was searched for consensus phosphorylation sites and was found to contain a motif for a calmodulin-dependent protein kinase II (CDPK-II) with threonine as the acceptor. It has been proposed that benzodiazepines produce their anticonvulsant effects by inhibiting brain calcium or calmodulin-dependent protein kinase. Therefore, the CDPK-II motif contained in the h β_{2L} insert could play a role in determining the pharmacology of GABA_A receptors containing h β_{2S} versus h β_{2L} (McKinley DD *et al.*, 1995. Cloning, sequence analysis and expression of two forms of mRNA coding for the human β_2 subunit of the GABA_A receptor. *Mol Brain Res* 28: 175-179). Changes in β subunit composition may alter receptor function and pharmacology *in vivo*. Modulation of receptor function by phosphorylation is also influenced by β subunit composition and contributes to increased inhibition during neuronal excitation (Russek SJ *et al.*, 2000. An initiator element mediates autologous down-regulation of the human type A γ -aminobutyric acid receptor β_1 subunit gene. *Proc Natl Acad Sci* 97: 8600-8605).

[0012] The β_2 subunits are most likely associated with the α_1 subunit (Stephenson FA, 1995. The GABA_A receptors. *Biochem J* 310: 1-9). The whole β_2 sequence (*GABRB2*) could be obtained by re-organising source sequences from the National Center for Biotechnology Information (NCBI) database by BLASTing the unorganised whole gene sequence with long form (NM_021911) and short form (NM_000813) mRNA. Reorganisation of the BLAST result yields the complete sequence and distribution of exons and introns of the β_2 subunit gene. The complete sequence of β_2 subunit gene covers

about 254 kb. The long form transcript variant contains 10 exons totalling 1.5 kb, and the short form transcript variant contains 9 exons totalling 1.4 kb. Exon 9 which contains 113 bases in sequence is deleted from the short form transcript.

[0013] While a number of reports have suggested a correlation between GABA_A receptors and schizophrenia (see above), the exact genetic basis for the correlation remains unclear. It is the object of the present invention to provide further genetic tools and methods to assist the diagnosis and treatment of schizophrenia.

[0014] Single Nucleotide Polymorphisms

[0015] Single nucleotide polymorphisms (SNPs) represent one of the most common forms of genetic variation. These polymorphisms occur when a single nucleotide (A, G, C or T) in the genome is altered. The most common form of SNP is the replacement of cytosine with thymine. SNPs generally tend to be evolutionarily stable from generation to generation and, as such, can be used to study specific genetic abnormalities throughout a population. SNPs often occur in protein coding regions and, as a result, may lead to the expression of a defective or variant form of a protein. Such polymorphisms can therefore serve as effective indicators of genetic disease. However, not all SNPs are found in protein coding regions of the genome. Some SNPs are located in noncoding regions, but these polymorphisms may also lead to altered protein expression. Specifically, SNP sites in noncoding regions may, for example, lead to differential and defective splicing. In diseases such as schizophrenia, where a large number of genes may influence the onset of the disease, SNPs can be used as diagnostic tools for identifying individuals with a predisposition for manifesting the disease, genotyping the patients suffering from the disease in terms of the genetic causes underlying the condition, and facilitating drug development based on the insight revealed regarding the role of target proteins in the pathogenesis process.

[0016] When SNPs are identified and genotyped in patients or in families, data must be analyzed to determine whether the association between an SNP and a disease is significant. Just as linkage is a relationship between loci, association is a relationship between alleles. Thus, an alternative to linkage mapping in families is to search for statistical associations between one allele and the disease. The idea behind this approach is that if one allele m1 can directly cause susceptibility to the disease, generally, possession of m1 is generally not necessary or sufficient for someone to develop the disease, but its frequency should increase in the proband population compared to unaffected controls. The same should also be true for all alleles in linkage disequilibrium (LD) with allele m1. Thus, SNP-based association studies can be performed in two ways: direct testing of a SNP with functional consequence for association, or using a SNP as a marker for LD. Therefore, a common core haplotype involving several SNPs should be more frequent in probands compared to controls.

[0017] The present invention seeks to provide a set of SNPs and their haplotypes for diagnoses of psychotic and affective disorders such as schizophrenia and identifying appropriate target proteins for drug development.

SUMMARY OF THE INVENTION

[0018] In one embodiment, the present invention provides an isolated polynucleotide having a nucleotide sequence comprising corresponding to SEQ ID NO: 1, the polynucleotide comprising a portion of the human *GABRB2* gene including a polymorphic site at position 1584 of intron 7.

[0019] In another embodiment, the invention provides a PCR primer set for amplifying regions of a polynucleotide corresponding to SEQ ID NO: 1, the primer set comprising a first primer having a sequence corresponding or complementary to a sequence corresponding to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12, and a second primer having a sequence corresponding or complementary to a sequence corresponding to SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 or SEQ ID NO: 13.

[0020] In yet another embodiment, the invention provides a method of predicting whether an individual is more or less likely to suffer from schizophrenia comprising:

- a) determining the nucleotide sequence from a nucleic acid sample from the individual; and
- b) identifying DNA sequences corresponding to one or more SNPs selected from the group consisting of: a novel SNP I7G1584T, and five known SNPs reported in dbSNP (<http://www.ncbi.nlm.nih.gov/SNP/>), namely rs1816071, rs1816072, rs194072, rs252944 and rs187269 of the human *GABRB2* gene, or other genetic markers in the same haplotype as, or in linkage disequilibrium with, one or more of the SNPs.

[0021] In yet another embodiment, the present invention provides a method of genotyping the schizophrenia-spectrum disorder of a patient in order to provide pharmacogenetic guidance for drug therapy for the patient, comprising:

[0022] a) determining the nucleotide sequence from a nucleic acid sample from a schizophrenic patient; and

[0023] b) identifying DNA sequences corresponding to one or more SNPs selected from the group consisting of: I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187269 of the human *GABRB2* gene, or other genetic markers in the same haplotype as, or in linkage disequilibrium with, one or more of the the SNPs.

[0024] In another embodiment, the invention provides a method of drug screening for identifying drugs for treating schizophrenic disorders, the method comprising:

- a) transfecting a vector into a eukaryotic expression system, the vector containing a DNA sequence

corresponding to at least a portion of the human *GABRB2* gene, the portion of the *GABRB2* gene including one or more SNPs chosen from the group consisting of: I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187269;

- b) expressing the vector in a cellular expression system;
- c) adding a drug to be screened into the cellular system;
- d) analyzing the expression of the *GABRB2* gene encoding GABA_A receptor β₂ subunit and also analysing the expression and resultant activity of the GABA_A receptor in the cellular system;
- e) determining the effect of the drugs on the expression of the GABA_A β₂ subunit and the GABA_A receptor, and the activity of the expressed GABA_A receptor in the cellular system; and,
- f) identifying those drugs that alter the levels of the expression of *GABRB2* gene.

BRIEF DESCRIPTION OF THE DRAWINGS

[0025] These and other features of the preferred embodiments of the invention will become more apparent in the following detailed description in which reference is made to the appended drawings wherein:

[0026] Figure 1a is a nucleotide sequence of Exon 7, Exon 8 and the Intron 7 between such exons of the human *GABRB2* gene comprising the three SNPs I7G1584T, rs1816071 and rs1816072.

[0027] Figure 1b is a nucleotide sequence of Exon 7, Exon 8 and the Intron 7 between such exons of the human *GABRB2* gene comprising the two SNPs rs194072 and rs252944.

[0028] Figure 2 is a nucleotide sequence of Exon 8, Exon 9 and the Intron 8 between such exons of the human *GABRB2* gene comprising the SNP rs187269.

[0029] Figure 3 shows the locations of the SNPs I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187269 of the human *GABRB2* gene.

[0030] Figure 4 shows data obtained from the sequencing gel of the flanking regions around the SNPs I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187269.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0031] The below terms are used throughout the present application and will be assumed to have the following definitions:

[0032] The term "allele" is used herein to refer to variants of a nucleotide sequence.

[0033] The term "antisense" is used herein, to refer to a complementary strand of a coding sequence of DNA or RNA. Such coding sequence may contain, for example, a SNP of interest. Copies of antisense polynucleotides can be introduced into a cell or organism to inhibit expression of a corresponding gene or to

alter the splicing of mRNA in specific regions. Antisense polynucleotides are entirely or substantially complementary to a target polynucleotide and have the ability to specifically hybridize to such target polynucleotide.

[0034] The terms "complementary" and "complement", as used herein, refer to polynucleotide sequences which are capable of base pairing with another polynucleotide throughout the complementary region.

[0035] The term "haplotype" refers to a series of known DNA sequences linked on a chromosome. The known DNA sequences can be in the form of SNPs or other markers. A haplotype may refer to a combination of polymorphisms found in an individual that may be associated with a phenotype.

[0036] The term "genotype" refers to the genetic constitution of an organism. More specifically, the term refers to the identity of alleles present in an individual. "Genotyping" of an individual or a DNA sample refers to identifying the nature, in terms of nucleotide bases, of a specific allele possessed by an individual at a known polymorphic site.

[0037] The term "polymorphism", as used herein, refers to the coexistence of more than one form of gene or portion thereof in a population. "Polymorphic" refers to the condition in which two or more variants of a specific genomic sequence can be found in a population. A "polymorphic site" refers to a locus at which variations in nucleotide sequence occur.

[0038] The terms "oligonucleotide" and "polynucleotide" as used in the present application refer to RNA, DNA or hybrid RNA/DNA sequences being of greater than one nucleotide in length. Such sequences may exist in either single or double-stranded form.

[0039] The term "PCR", as used herein, refers to the polymerase chain reaction. PCR is a method of amplifying a DNA base sequence using a heat stable polymerase and a pair of primers, one primer complementary to the (+)-strand at one end of the sequence to be amplified and the other primer complementary to the (-) strand at the other end of the sequence to be amplified. Newly synthesized DNA strands can subsequently serve as templates for the same primer sequences and successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR can be used to detect the existence of a defined sequence in a DNA sample.

[0040] The term "primer", as used herein, refers to a short single-stranded oligonucleotide capable of hybridizing to a complementary sequence in a DNA sample. The primer serves as an initiation point for template dependent DNA synthesis. Deoxyribonucleotides can be added to a primer by a DNA polymerase. A "primer pair" or "primer set" refers to a set of primers including a 5' upstream primer that hybridizes with the 5' end of the DNA sequence to be amplified and a 3', downstream primer that hybridizes with the complement of the 3' end of the DNA sequence to be amplified.

[0041] The term "exon" refers to the protein coding DNA sequence of a gene.

[0042] The term "intron" or "intronic region" refers to DNA base sequences interrupting the protein-coding sequences of a gene. These sequences are transcribed into RNA but are cut out of the RNA before it is translated into protein.

[0043] The present invention relates, generally, to single nucleotide polymorphisms (SNPs) associated with the etiopathogenesis of schizophrenia. As found by the present inventors, individuals possessing certain SNPs, or their complementary regions, have been found to have an increased susceptibility to a schizophrenia spectrum disorder. These disorders have been linked to mutations of the *GABRB2* gene. As indicated above, the *GABRB2* gene encodes the β_2 subunit of human gamma-aminobutyric acid type A receptor.

[0044] In one aspect, the present invention provides an association of certain SNP sites with schizophrenia disorders. These SNPs are as follows: rs1816071, rs1816072, rs194072, rs252944, and rs187269. These SNPs are present in the introns preceding and following Exon 8 of *GABRB2*, and the haplotype or haplotypes containing one or more of these six SNPs. The above listed SNPs are known in the art but have not been previously associated with schizophrenia disorders.

[0045] According to another embodiment, the present invention provides a further, previously unknown SNP, also associated with schizophrenia disorders. This SNP, referred to herein as SNP I7G1584T, is found in intron 7 of the *GABRB2* gene. This intron is the region between Exons 7 and 8 of the aforementioned gene. The methodology used to identify this SNP is provided below.

[0046] Results of linkage disequilibrium or association analysis of the above mentioned six SNPs are shown in Tables 1 and 2(provided herein below), which present data concerning the correlation between each allele and genotype frequency with schizophrenia. In Tables 1 and 2, "SCH" represents schizophrenic patients and "CON" represents normal controls. Statistical testing of the data shows that the six SNPs I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187269 in the β_2 subunit gene are significantly associated at the allelic level with schizophrenia, with $p < 0.05$; and that the five SNPs I7G1584T, rs1816071, rs194072, rs252944 and rs187269 are significantly associated at the genotypic level with schizophrenia, with $p < 0.05$. Therefore, these various SNPs may serve as potential genetic factors linked to the etiopathogenesis of schizophrenia.

[0047] Accordingly, in one aspect, the present invention provides a method of detecting the SNPs I7G1584T, rs1816071, rs1816072, rs194072, rs252944, and rs187269, and their associated haplotypes, for the diagnosis of susceptibility to schizophrenia, the genotyping of cases of schizophrenia, and to render GABA_A receptors containing a β_2 subunit as potentially useful target protein systems for the screening and development of drugs to treat the disease.

[0048] Figure 1a depicts a nucleotide sequence containing Exon 7, Exon 8 and the Intron 7 between such exons in the human *GABRB2* gene. In Figure 1a, the SNP I7G1584T is identified by a rectangular box with solid lines. The SNP rs1816071 is identified by a rectangular box with dashed lines, and the SNP rs1816072 is identified by a rectangular box with a double solid line. Exon 7 is underlined with a double dashed line. Exon 8 is underlined with a single dashed line. The PCR-amplified region containing I7G1584T, rs1816071 and rs1816072 is underlined with a solid line.

[0049] In Figure 1b, the SNP rs194072 is identified by a rectangular box with solid lines. The SNP rs252944 is identified by a rectangular box with dashed lines. Exon 7 is underlined with a double dashed line. Exon 8 is underlined with a single dashed line. The PCR-amplified region containing rs194072 is underlined with a solid line. The PCR-amplified region containing rs252944 is shown in bold type.

[0050] Referring now to Figure 2, a nucleotide sequence of Exon 8, Exon 9 and the Intron 8 between such exons of the human *GABRB2* gene is presented. The SNP rs187269 is identified by a rectangular box with a solid line. Exon 8 is shown in bold type and Exon 9 is underlined with a dashed line. The PCR-amplified region is underlined with a solid line.

[0051] The above-mentioned figures present the SNPs which have been associated with the schizophrenia.

[0052] It is another aspect of the present invention to provide a method of screening and diagnosing the occurrence and genotype of schizophrenia by analyzing the sequences of the GABA receptor β_2 gene, namely *GABRB2*, in order to identify the allele and/or genotype and/or haplotype of the subject at SNP I7G1584T, rs1816071, rs1816072, rs194072 or rs252944 or rs187269 or a combination including any number of these six SNPs. The method includes obtaining human DNA in sufficient quantity for sequence analysis, and identifying the nature of the base at one or more of these SNP positions in the human *GABRB2* gene. The method used may involve common techniques such as PCR, under the same conditions and using the same primers as described below in the examples provided for detection of nucleotide sequences associated with schizophrenia, followed by DNA sequence analysis. Alternate primers upstream and downstream of these six SNP positions may also be used and may be determined by one skilled in the art without undue experimentation. Any other methods useful for SNP genotype and haplotype analysis may be applied to identify the variants at the six SNP sites and other markers in the same haplotype as, or in linkage disequilibrium with, the six SNPs.

[0053] The examples contained in the present application include methods for screening and/or diagnosing schizophrenic disorders. In summary, the invention provides that if the base T is found at I7G1584T, the subject may be at higher risk for developing schizophrenia than if G is found at this position.

If the base G is found at rs1816071, the subject may be at higher risk for developing schizophrenia than if A is found at this position. If the base C is found at rs1816072 and/or rs194072 and/or rs187269, the subject may be at higher risk for developing schizophrenia than if T is found at this position. Likewise, if the base C is found at position rs252944, the subject may be at a higher risk for developing schizophrenia than if G is found at this position.

[0054] Referring to Figure 3, a schematic diagram presenting the distribution of exons in the genome nucleotide sequence of the human *GABRB2* gene is provided. The figure depicts the locations of the SNP sites I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187269 in *GABRB2*, which can be used in an embodiment of the present invention for determining if an individual has a predisposition for schizophrenia.

[0055] The above mentioned polymorphisms can be used in diagnostic tests in order to identify individuals who have a predisposition for developing schizophrenia. Such diagnostic tests may utilize a number of technologies known in the art including, use of DNA chip methods (such as GenFlexTM Tag, Affymetrix) and DNA immobilization on beads (such as SIGNETTM Y-SNP Identification System, Marligen Bioscience, Inc.), ABI Prism[®] SNP^aPshotTM Multiplex System (Applied Biosystems Inc.) and PyrosequencingTM (Pyrosequencing AB). Diagnostic tests can also be conducted using allele specific primers, allele specific probes, directing sequencing of the intron of interest, and denaturing gradient gel electrophoresis. The present invention therefore provides a method of diagnosing an individual with schizophrenia, or an individual with a predisposition to schizophrenia, by determining the presence or absence of a *GABRB2* haplotype. Such haplotype would include the SNP sites I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187269.

[0056] In yet another aspect of the present invention, synthetic or recombinant DNA molecules are provided for diagnostic purpose. Such molecules comprise a sequence encompassing one or two or three of the SNPs I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187269, in one or both their allelic forms, and their flanking regions, and any haplotype or haplotypes associated with one or more of these six SNPs, as well as any genetic locus or loci in linkage disequilibrium with the six SNPs, with respect to one or both DNA strands of the *GABRB2* gene.

[0057] In an additional embodiment of the present invention, a method is provided for screening therapeutic drugs for treatment of schizophrenia, based on the correlation between the novel SNP I7G1584T, the SNPs rs1816071, rs1816072, rs194072, rs252944, and rs187269, and the disease. Because these six SNPs are located in the intron regions of *GABRB2*, they may modulate the synthesis mRNA splicing and the activity of GABA_A receptors containing the β₂ subunit. To detect such

modulation, a *GABRB2* gene containing different combinations of the different allelic forms of these six SNPs may be cloned, and expressed along with other *GABA_A* subunit genes, by means of appropriate expression vectors in cell lines such as P12 (ATCC, The Global Bioresource Center™), and using commonly used transfection kits such as the CellPfect Transfection Kit (Amersham Pharmacia Biotech, Inc., USA), and ProFection® Mammalian Transfection Systems (Promega Corporation). The cell line may or may not be of neuronal origin. Transfection efficiency can be enhanced by using a number of reagents known in the art including, for example, calcium phosphate (Life Technologies Inc.).

[0058] In the event that one or more of the SNP's I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187289, in their schizophrenia-associated allelic form, should alter the expressed activity of *GABA_A* receptor through a modification of the short form/long form ratio, some structural feature, or the amount of the expressed β_2 subunit, the above mentioned cellular system also may be employed to screen and search for compounds that can restore the normal level of expressed activity of *GABA_A* receptor. Such compounds may be potentially useful candidate drugs for the treatment of schizophrenia.

[0059] The invention further provides kits for detection of SNP sites associated with schizophrenia.

[0060] To detect the SNPs of interest by DNA sequencing or other genotyping methods, a PCR is performed to amplify the DNA segment of a test subject containing one or more of the SNPs I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187269, and the PCR products are subjected to DNA sequencing or other genotyping methods such as single-base extension or microarray-based sequence-specific oligonucleotide probe hybridization, to determine the allelic form or forms of the polymorphism(s). The results may be analysed by computer software packages such as POLYPHRED™ and CONSED™ for DNA sequencing data, or other suitable software. A kit that may serve such detection may contain, for example, one or more of the following components including: PCR primers, allele specific probes, DNA polymerase, PCR reaction buffer, magnesium chloride and four deoxynucleotides for use in a PCR reaction or extension of probe sequences. In addition, if a sequencing reaction is conducted a kit may also include, sequencing primers, DNA polymerase, four labelled dideoxynucleotides, and four un-labelled deoxynucleotides.

[0061] In cases where genotyping methods do not require PCR amplification of DNA are employed, the DNA of a test subject can be directly used in experimental characterization of the six SNPs, and the haplotype or haplotypes associated with the six SNPs.

[0062] The present invention also provides a method of drug screening comprising the steps of:

[0063] (a) Transfected a vector into a eukaryotic expression system, the vector containing the DNA sequence corresponding to part or all of the human *GABRB2* gene, by itself or along with other genes encoding the proteins of the human *GABA_A* receptor;

[0064] (b) Expressing the vector in the cellular expression system;

- [0065] (c) Adding a drug to be screened into the cellular system
- [0066] (d) Analyzing the gene expression of the *GABRB2* gene encoding the GABA_A receptor β₂ subunit, the *GABRB2* gene being in all possible allelic combinations relating to the SNPs I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187269, and also analysing the expression and resultant activity of the GABA_A receptor in the cellular system.
- [0067] (e) Determining the effect of chemical compounds or preparations on the cellular system with respect to the expression of GABA_A β₂ subunit and the GABA_A receptor, and the activity of the expressed GABA_A receptor in the cellular system.
- [0068] The chemical compounds or preparations so identified are potentially useful candidate drugs for the treatment of schizophrenia.
- [0069] While the novel SNP I7G1584T, and the SNPs rs1816071, rs1816072, rs194072, rs252944 and rs187269 may be used singly or jointly for diagnostic or drug development purposes, one or more genetic markers belonging to the same haplotype as, or in linkage disequilibrium with, one or more of these six SNPs, may also be employed for these purposes.
- [0070] Furthermore, while the PCR and DNA sequencing methods described below in Example 1, and similar methods such as DNA sequencing by means of pyrosequencing (Pyrosequencing AB), can reveal the genotype of a test DNA sample in terms of the SNPs I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187269, alternative methods can also be employed for this purpose. Such alternate methods include the use of DNA chip methods (such as GenFlex™ Tag, Affymetrix) and DNA immobilization on beads (such as SIGNET™ Y-SNP Identification System, Marligen Bioscience, Inc.), instead of DNA sequencing, and methods using single DNA molecule sequencing instead of PCR (such as ABI Prism® SNPaPshot™ Multiplex System, Applied Biosystems Inc.).
- [0071] The examples presented below are provided to illustrate the present invention and are not meant to limit the scope of the invention as will be apparent to persons skilled in the art.
- [0072] **EXAMPLE 1: Identification of the Novel SNP site of the Invention:**
- [0073] The novel SNP I7G1584T of the invention was identified in the method as described below.
- [0074] For discovery of SNPs within the region of interest, specific primers were designed in an adjacent-primer-overlapping-200-base-pair manner by using the online primer designation program, Primer3™ (http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). The specificity of each suggested primer to the human genome was checked through BLAST™ (National Center for Biotechnology Information - <http://www.ncbi.nlm.nih.gov/BLAST>). Only both forward and reverse primers with less than 5 hits to human genome were considered as specific primers and employed.

[0075] PCR was preformed in a final volume of 20 µl containing: 10 ng sample DNA from either controls or patients; 0.075 µmole/L of each primer; 500 µmol/L of each dNTP; 2.5 mmol/L MgCl₂; and 1 U Taq™ polymerase (Amersham Pharmacia Biotech, Inc, USA). Gradient PCR was engaged initially to determine the optimum annealing temperature for each pair of primers. Examples of primer sequences and their optimum annealing temperatures are listed in Table 3. PCR amplification consisted of denaturation at 94°C for 5 min followed by 40 cycles of 1 min at 94°C, 1 min at optimum annealing temperature for each pair of primers to DNA template, 1.5 min at 72°C and a final extension step at 72°C for 5 min. PCR products were then resolved using 1.5% agarose gel electrophoresis and staining with ethidium bromide to confirm desired and specific products generated. PCR products were purified by MultiScreen™ PCR₉₆ Purification kit (Millipore Corporation, Bedford, USA).

[0076] Discovery of SNPs within the region of interest were preformed by auto-sequencing of PCR fragments on both strands. The sequencing reactions contained: 2 µl BigDye™ Terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems); 5µl purified PCR products; and 1 mmol/L of primer. Sequencing cycling conditions consisted of 1 min denaturation at 96°C followed by 34 cycles of 96°C for 30sec, 50°C for 30sec and 60°C for 3min. Sequencing products were purified by AutoSeq96™ Plates containing DNA Grade Sephadex™ G-50 (Amersham Pharmacia Biotech, Inc, USA). Purified sequencing products were then denatured at 95°C for 5 min with addition of 5µl Hi-Deionized Formamide. Denatured sequencing products were run on the ABI Prism model 3100 DNA sequencer according to ABI protocols.

[0077] Sequence data were aligned and analyzed for SNPs by POLYPHRED™ software (Nickerson DA, Tobe VO & Talyor SL, 1997 Nucleic Acids Res. 15; 25: 2745-51) and CONSED™ software (Gordon D, Abajian C and Green P, 1998 Genome Res. 8: 195-202).

EXAMPLE 2: Detection of Nucleotide Sequences Associated with Schizophrenia

[0078] This example describes the protocol utilized to find and test for the presence of one or more the above-mentioned SNPs. In this example, PCR-amplified products are synthesized to encompass the target regions of human GABA_A receptor β₂ subunit of the GABRB2 gene. A pair of primers, specific to each of these regions, and which can be used for amplification, are shown in Table 3.

Table 3 The Primers of β₂ Subunit Genes for Both PCR and DNA Sequencing

Cluster ID of dbSNP	Forward primer	Reverse primer	Optimum annealing temperature for PCR
------------------------	----------------	----------------	--

I7G1584T	atggagggaaagggtccatatctagt (SEQ ID NO:12)	cctctaagctgtaatcggaaggta (SEQ ID NO:13)	62°C
rs1816071	atggagggaaagggtccatatctagt (SEQ ID NO:10)	cctctaagctgtaatcggaaggta (SEQ ID NO:11)	62°C
rs1816072	atggagggaaagggtccatatctagt (SEQ ID NO:8)	cctctaagctgtaatcggaaggta (SEQ ID NO:9)	62°C
rs194072	taccttccgattacagcttagagg (SEQ ID NO:2)	tggagaggactctaggtaacttt (SEQ ID NO:3)	64°C
rs252944	cacaatgattttccgagaccat (SEQ ID NO:4)	ttgttaaagctattgtccagcaagt (SEQ ID NO:5)	62°C
rs187269	agcacttgctgcactaacagaata (SEQ ID NO:6)	agacaaatgcctaattgcctctgg (SEQ ID NO:7)	62°C

[0079] **PCR Amplification of SNP Containing Regions and Sequencing of Amplified Regions**

[0080] The following reagents were used for amplification reactions for amplifying the regions of interest: 2 µl of PCR buffer (Amersham Pharmacia Biotech, Inc, USA); 2.5 mM MgCl₂; 500 µM dNTPs; 0.075 µM of each primer; 10 ng DNA; and 1 U Taq™ DNA polymerase (Amersham Pharmacia Biotech, Inc., USA); in a total volume of 20 µl.

[0081] PCR amplification was performed in the PTC-200™ Peltier thermal-cycler (MJ Research, Inc.) and RoboCycler™ (Stratagene, USA) using 96-well microplates under the following thermal cycle conditions: 5 minutes at 94 °C for denaturation; and 40 cycles for optimal DNA amplification that entailed denaturation at 94 °C for 30 seconds, annealing at 60 °C – 62 °C for 30 seconds, and polymerization at 72 °C for 1.5 minutes.

[0082] The PCR products were purified using a MultiScreen®-PCR kit, (Millipore Corporation, Bedford, USA), and were directly sequenced using a BigDye™ Terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems) under the following conditions: 96 °C for 1 minute followed by 34 cycles of 96 °C for 30 seconds, 50 °C for 15 seconds, and 60 °C for 3 minutes.

[0083] Sequencing products were purified by AutoSeq96™ Plates containing DNA Grade Sephadex™ G-50 (Amersham Pharmacia Biotech, Inc, USA). Purified sequencing products were then denatured at 95°C for 5 min with addition of 5µl Hi-Deionized Formamide. Denatured sequencing products were run on the ABI Prism model 3100 DNA sequencer according to ABI protocols. Sequence data were aligned and analyzed for SNPs by POLYPHRED™ software (Nickerson DA, Tobe VO & Taylor SL, 1997 Nucleic Acids Res. 15; 25: 2745-51) and CONSED™ software (Gordon D, Abajian C

and Green P, 1998 Genome Res. 8: 195-202). Each PCR product was sequenced from both ends using the same primers as those utilized for the DNA amplification described above.

[0084] The DNA sequencing results using this procedure are shown in Table 1. This table shows the nature of the SNP bases in samples from control (CON) and schizophrenic (SCH) subjects in term of the allelic form of the six SNPs examined.

[0085] Although one method of detecting the six polymorphic sites associated with schizophrenia is provided above, it will be understood by persons skilled in the art that other detection methods may also be utilized. For example, detection can also be accomplished, inter alia, through allele specific probes designed to identify the presence or absence of an individual SNP site, allele specific primer extension reactions, and single base primer extension reactions.

[0086] **EXAMPLE 3: Genotyping of I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187269 polymorphisms**

[0087] For the novel SNP I7G1584T, and the five SNPs rs1816071, rs1816072, rs194072, rs252944 and rs187269, the DNA sequencing results in Table 1 from healthy Controls, and Schizophrenics satisfying DSM IV criteria (American Psychiatric Association, 1994) were analysed by genotyping in order to determine whether the aforementioned SNPs were associated with an increased risk of schizophrenia. Identification of SNPs was conducted using the primers and sequencing method as described in Example 2.

[0088] **Table 1: Forms of SNPs in the GABRB2 Gene**

Cluster ID of dbSNP	Allele			Genotype		
		CON	SCH		CON	SCH
I7G1584T	G	163	185	G/G	72	72
	T	21	55	G/T	19	41
	Total	184	240	T/T	1	7
				Total	92	120
rs1816071	A	137	142	A/A	56	51
	G	37	82	A/G	25	40
	Total	174	224	G/G	6	21
				Total	87	112

rs1816072	T	131	125	T/T	44	37
	C	71	105	T/C	43	51
	Total	202	230	C/C	14	27
				Total	101	115
rs194072	T	173	184	T/T	77	73
	C	23	56	T/C	19	38
	Total	196	240	C/C	2	9
				Total	98	120
rs252944	G	240	148	G/G	104	55
	C	36	52	G/C	32	38
	Total	276	200	C/C	2	7
				Total	138	100
rs187269	T	284	188	T/T	117	70
	C	58	74	T/C	50	48
	Total	342	262	C/C	4	13
				Total	171	131

[0089] As shown in Table 2, the Chi-square test for comparing the genotypes of Controls (CON) and Schizophrenics (SCH) shows a very significant increase of homozygote T/T carriers of novel SNP I7G1584T, homozygote G/G carriers of rs1816071 and homozygote C/C carriers of rs1816072, rs194072, rs252944 and rs187269 among schizophrenics. The comparison of allele frequencies also indicates a highly significant increase in T of novel SNP I7G1584T, G of rs1816071 and C of rs1816072, rs194072, rs252944 and rs187269 in Schizophrenics in comparison to Controls.

[0090] Table 2 shows the frequency distribution of genotypes and alleles for the novel SNP I7G1584T, and the SNPs rs1816071, rs1816072, rs194072, rs252944 and rs187269 polymorphisms. Table 2 shows the *p* values from the Chi-square test, odds ratios (OR) and 95% confidence interval (95% CI) in comparing the following samples: a) 120 Schizophrenics (SCH) and 92 Controls (CON) for novel SNP I7G1584T; b) 112 Schizophrenics and 87 Controls for rs1816072; c) 115 Schizophrenics and 101 Controls for rs1816072; d) 120 Schizophrenics and 98 Controls for rs194072; e) 100 Schizophrenics and 138 Controls for rs252944; and f) 131 Schizophrenics

and 171 Controls for rs187269. All the Controls and Schizophrenics were *Han Chinese*. The statistic software Prism3™ version 3.02 was used for allele and genotype significance testing.

[0091] Table 2: Association of SNPs in the GABRB2 Gene with Schizophrenia.

Cluster ID of dbSNP	Allele					
	I7G1584T	rs1816071	rs1816072	rs194072	rs252944	rs187269
p Value	0.0022	0.0009	0.0266	0.0018	0.0003	0.0009
OR	2.308	2.138	1.55	2.289	2.342	1.927
95% CI	1.338-3.981	1.358-3.366	1.051-2.285	1.350 - 3.882	1.460-3.755	1.305-2.847
Genotype						
Cluster ID of dbSNP	I7G1584T	rs1816071	rs1816072	rs194072	rs252944	rs187269
p Value	0.011	0.0109	0.1044	0.0125	0.0018	0.0031
OR	--	--	--	--	--	--
95% CI	--	--	--	--	--	--

[0092] Table 4 below shows the estimated frequencies for certain haplotypes of the six SNPs and the significance of their association with schizophrenia (SCH) in comparison to unaffected controls (CON). Maximum likelihood haplotype frequencies between possible SNP haplotypes were estimated by the Expectation-Maximization algorithm (Slatkin M, Excoffier L, 1996). Testing for linkage disequilibrium in genotypic data using the expectation-maximization algorithm. Heredity 76:377-383) using the program SNPHAP™ (<http://www.hgmp.mrc.ac.uk/Menu/Help/snphap>) under Hardy-Weinberg assumption of gamete independence. Association analyses were performed by comparing the haplotype frequencies of Controls and Schizophrenics through the Chi-square test. Association of schizophrenia and estimated two-loci and six-loci haplotype were accessed by CLUMPTM (<http://www.hgmp.mrc.ac.uk/Registered/Help/clump/>) (Sham PC and Curtis D, 1995. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. *Ann Hum Genet* 59: 97-105) to yield the Chi-square value and its corresponding p value.

[0093] The novel SNP I7G1584T, and the SNPs rs1816071, rs1816072, rs194072 and rs252944 SNP are located between Exons 7 and 8, and the rs187269 SNP is located between Exon 8 and 9. Exon 9 is present in the long form variant of the β_2 subunit of GABA_A receptor mRNA but absent from the short form variant. These six SNPs are thus located close to a region that may play a role in modulating the properties and/or quantity of β_2 incorporated into GABA_A receptors, including but not limited to the alternative splicing of the *GABRB2* mRNA to yield the short form versus the long form of β_2 .

Table 4: Haplotype Frequencies and Significance of Association with Schizophrenia

Haplotype	Frequency %		χ^2, df^*	P (OR; 95%CI)
	CON	SCH		
I7G1584T-rs1816071			16.95, 3	0.00074
G-A	76.81	59.85		
G-G	11.78	18.02		
T-A	0.00	3.75		
T-G	11.41	18.38		
T-G vs. G-A + G-G + T-A			3.70, 1	0.054 (1.725; 0.9855-3.019)
I7G1584T-rs187269			12.89, 3	0.0049
G-T	81.70	67.38		
G-C	6.9	11.36		
C-T	1.45	3.10		
C-C	9.95	18.16		
C-C vs. GT + G-C + C-T			6.738, 1	0.0094 (2.04; 1.182-3.523)
rs1816071-rs1816072			17.44, 3	0.000583
A-T	66.71	48.02		
A-C	12.36	15.76		
G-T	1.31	6.16		
G-C	19.62	30.07		
G-C vs. A-T + A-C + G-T			5.44, 1	0.0197 (1.733; 1.089-2.758)
rs1816071-rs187269			22.90	0.000043
A-T	75.0	55.13		
A-C	2.51	9.55		
G-T	8.98	13.73		
G-C	13.51	21.59		
G-C vs. A-T + A-C + G-T			5.45	0.0197 (1.774, 1.092-2.883)
rs1816072-rs194072			12.73, 3	0.0053
T-T	63.55	52.89		
T-C	0.78	1.72		
C-T	23.95	21.97		
C-C	11.71	23.42		
C-C vs. T-T + T-C + C-T			11.45, 1	0.00072 (2.284; 1.404-3.716)
rs194072-rs252944			8.39, 3	0.03868
T-G	85.23	73.85		
T-C	0.38	1.24		
C-G	0.46	1.03		
C-C	13.92	23.89		

C-C vs. T-G + T-C + C-G			6.77, 1	0.009281 (1.906; 1.167-3.112)
rs252944-rs187269			26.24, 3	0.000009
G-T	80.10	69.45		
G-C	6.79	7.76		
C-T	4.18	0.72		
C-C	8.93	22.06		
C-C vs. G-T + G-C + C-T			20.87, 1	0.000005 (2.960; 1.829-4.808)
rs194072-rs187269			26.83, 3	0.000007
T-T	78.62	68.01		
T-C	5.96	8.36		
C-T	5.30	0.64		
C-C	10.12	22.98		
C-C vs. T-T + T-C + C-T			17.89, 1	0.000024 (2.624; 1.660-4.148)
rs194072-rs252944-rs187269			30.72, 7	0.000072
T-T-T	80.39	65.17		
T-C-C	5.54	7.55		
T-C-T	0.00	0.00		
T-C-C	0.00	1.09		
C-T-T	0.00	0.00		
C-T-C	0.45	1.08		
C-C-T	4.89	1.19		
C-C-C	8.36	23.89		
C-C-C vs others			17.21, 1	0.000034 (2.857; 1.713-4.766)
I7G1584T-rs194072-rs252944-rs187269			29.29, 15	0.015
G-T-T-T	81.97	65.69		
G-T-T-C	09.13	7.09		
G-T-C-T	0.00	0.00		
G-T-C-C	0.00	1.23		
G-C-T-T	0.00	0.81		
G-C-T-C	0.00	1.50		
G-C-C-T	1.85	0.02		
G-C-C-C	0.59	1.25		
T-T-T-T	0.00	1.33		
T-T-T-C	0.00	0.00		
T-T-C-T	0.00	0.00		
T-T-C-C	0.00	0.00		
T-C-T-T	0.00	0.00		
T-C-T-C	0.00	0.00		
T-C-C-T	2.18	1.40		
T-C-C-C	4.29	19.68		
T-C-C-C vs others			12.79, 1	0.0003 (4.860; 1.888-12.51)

Note: df= degree of freedom

[0094] EXAMPLE 4: Method for Screening Enhanced Susceptibility to Schizophrenia and for Genotyping Schizophrenics

[0095] Example 2 describes a method for determining the nature of the novel SNP I7G1584T, and the SNPs rs1816071, rs1816072, rs194072, rs252944 and rs187269 in Control subjects and Schizophrenic patients. Example 3 shows that a base T in SNP I7G1584T, a base G in rs1816071 and a base C in rs1816072, rs194072, rs252944 and rs187269 signifies an increased risk of schizophrenia. Furthermore, these six SNPs provide a basis for screening for enhanced susceptibility for schizophrenia, and genotyping schizophrenia patients with the aim of applying pharmacogenetics to determine the optimal therapeutic to be employed for their treatment.

[0096] The same procedures employed in Example 2 also can be performed on test subjects with unknown susceptibility to schizophrenia or schizophrenic patients with unknown genotype. In either case, the procedures employed will reveal the genotype of the test DNA sample with respect to the bases at the SNP positions the novel SNP I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187269. The resultant genotype in turn will indicate whether the test subject carries enhanced genetic susceptibility to schizophrenia. In the case of a patient known to be a schizophrenic, the genotype will provide a basis for diagnostic classification and for pharmacogenetic profiling towards achieving optimizing therapy.

[0097] To perform genotyping using the PCR and sequencing procedures as described in Example 2, the following sequences, or sequences similar to them, will be required.

[0098] **Description of Sequence Listings**

[0099] SEQ ID NO:1: The native DNA sequence of Exon 7, Intron 7, Exon 8, Intron 8 and Exon 9 of the human *GABRB2* gene, with variation noted at positions 1584, 1803, 2103, 3106 and 3424 of intron 7, and position 1265 of Intron 8

[00100] SEQ ID NO:2 is the nucleotide sequence for the forward primer used for the amplification of the SNP at position 3106 of Intron 7, corresponding to rs194072, of the human *GABRB2* gene.

[00101] SEQ ID NO:3 is the nucleotide sequence for the reverse primer used for the amplification of the SNP at position 3106 of Intron 7, corresponding to rs194072, of the human *GABRB2* gene.

[00102] SEQ ID NO:4 is the nucleotide sequence for the forward primer used for the amplification of the SNP at position 3424 of Intron 7, corresponding to rs252944, of the human *GABRB2* gene.

[00103] SEQ ID NO:5 is the nucleotide sequence for the reverse primer used for the amplification of the SNP at position 3424 of Intron 7, corresponding to rs252944, of the human *GABRB2* gene.

[00104] SEQ ID NO:6 is the nucleotide sequence for the forward primer used for the amplification of the SNP at position 1265 of Intron 8, corresponding to rs187269, of the human *GABRB2* gene.

[00105] SEQ ID NO:7 is the nucleotide sequence for the reverse primer used for the amplification of the SNP at position 1265 of Intron 8, corresponding to rs187269, of the human *GABRB2* gene.

[00106] SEQ ID NO:8 is the nucleotide sequence for the forward primer used for the amplification of the SNP at position 2103 of Intron 7, corresponding to rs1816072, of the human *GABRB2* gene.

[00107] SEQ ID NO:9 is the nucleotide sequence for the reverse primer used for the amplification of the SNP at position 2103 of Intron 7, corresponding to rs1816072, of the human *GABRB2* gene.

[00108] SEQ ID NO:10 is the nucleotide sequence for the forward primer used for the amplification of the SNP at position 1803 of Intron 7, corresponding to rs1816071, of the human *GABRB2* gene.

[00109] SEQ ID NO:11 is the nucleotide sequence for the reverse primer used for the amplification of the SNP at position 1803 of Intron 7, corresponding to rs1816071, of the human *GABRB2* gene.

[00110] SEQ ID NO:12 is the nucleotide sequence for the forward primer used for the amplification of the SNP at position 1584 of Intron 7, corresponding to I7G1584T, of the human *GABRB2* gene.

[00111] SEQ ID NO:13 is the nucleotide sequence for the reverse primer used for the amplification of the SNP at position 1584 of Intron 7, corresponding to I7G1584T, of the human *GABRB2* gene.

[00112] The various publications and published methods mentioned above are incorporated herein by reference.

Although the invention has been described with reference to certain specific embodiments, various modifications thereof will be apparent to those skilled in the art without departing from the spirit and scope of the invention as outlined in the claims appended hereto.

CLAIMS

1. An isolated polynucleotide having a nucleotide sequence comprising corresponding to SEQ ID NO: 1, said polynucleotide comprising a portion of the human *GABRB2* gene including a polymorphic site at position 1584 of intron 7.
2. The isolated polynucleotide of claim 1 wherein the nucleotide at position 1584 of Intron 7 is selected from G or T.
3. An isolated polynucleotide having a nucleotide sequence which is complementary to the polynucleotide of claim 2.
4. A PCR primer set for amplifying regions of a polynucleotide corresponding to SEQ ID NO: 1, said primer set comprising a first primer having a sequence corresponding or complementary to a sequence corresponding to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12, and a second primer having a sequence corresponding or complementary to a sequence corresponding to SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11 or SEQ ID NO: 13.
5. A method of predicting whether an individual is more likely to suffer from schizophrenia comprising the identification of DNA sequences corresponding to one or more SNPs selected from the group consisting of: SNPs at positions 1584, 1803, 2103, 3106, and 3434 of intron 7, and position 1265 of intron 8 of the human *GABRB2* gene on one or two of the individual's chromosomes, or other genetic markers in the same haplotype as, or in linkage disequilibrium with, one or more of said SNPs.
6. The method of claim 5 wherein the presence of a C at position 3106 of Intron 7 indicates that the individual is more likely to suffer from schizophrenia.
7. The method of claim 5 wherein the presence of a C at position 3424 of Intron 7 indicates that the individual is more likely to suffer from schizophrenia.
8. The method of claim 5 wherein the presence of a C at position 1265 of Intron 8 indicates that the individual is more likely to suffer from schizophrenia.

9. The method of claim 5 wherein the presence of a C at position 2103 of Intron 7 indicates that the individual is more likely to suffer from schizophrenia.
10. The method of claim 5 wherein the presence of a G at position 1803 of Intron 7 indicates that the individual is more likely to suffer from schizophrenia.
11. The method of claim 5 wherein the presence of a T at position 1584 of Intron 7 indicates that the individual is more likely to suffer from schizophrenia.
12. A method of genotyping an individual in order to determine a clinical and pharmacogenetic classification of a schizophrenia-spectrum disorder of the individual suffering from such disorder, said method comprising the identification of DNA sequences corresponding to one or more SNPs selected from the group consisting of: SNPs at positions 1584, 1803, 2103, 3106, and 3434 of intron 7, and position 1265 of intron 8 of the human *GABRB2* gene on one or two of the individual's chromosomes, or other genetic markers in the same haplotype as, or in linkage disequilibrium with, one or more of said SNPs.
13. The method of claim 12 wherein the presence of a C at position 3106 of Intron 7 indicates that the schizophrenia-spectrum disorder of the individual has a genotype that includes the presence of a C at position 3106 of Intron 7 of *GABRB2*.
14. The method of claim 12 wherein the presence of a C at position 3424 of Intron 7 in either one or two chromosome indicates that the schizophrenia-spectrum disorder of the patient has a genotype that includes the presence of a C at position 3424 of Intron 7 of *GABRB2* in either one or two chromosomes.
15. The method of claim 12 wherein the presence of a C at position 1265 of Intron 8 in either one or two chromosome indicates that the schizophrenia-spectrum disorder of the patient has a genotype that includes the presence of a C at position 1265 of Intron 8 of *GABRB2* in either one or two chromosomes.
16. The method of claim 12 wherein the presence of a C at position 2103 of Intron 7 in either one or two chromosome indicates that the schizophrenia-spectrum disorder of the patient has a genotype that includes the presence of a C at position 2103 of Intron 7 of *GABRB2* in either one or two chromosomes.
17. The method of claim 12 wherein the presence of a G at position 1803 of Intron 7 in either one or two chromosome indicates that the schizophrenia-spectrum disorder of the patient has a genotype that includes

the presence of a G at position 1803 of Intron 7 of *GABRB2* in either one or two chromosomes.

18. The method of claim 12 wherein the presence of a T at position 1584 of Intron 7 in either one or two chromosome indicates that the schizophrenia-spectrum disorder of the patient has a genotype that includes the presence of a T at position 1584 of Intron 7 of *GABRB2* in either one or two chromosomes.

19. A method of drug screening for identifying drugs for treating schizophrenic disorders, the method comprising:

- a) transfecting a vector into a eukaryotic expression system, said vector containing a DNA sequence corresponding to at least a portion of the human *GABRB2* gene, said portion of the *GABRB2* gene including one or more SNPs chosen from the group consisting of: I7G1584T, rs1816071, rs1816072, rs194072, rs252944, and rs187269;
- b) expressing said vector in a cellular expression system;
- c) adding a drug to be screened into said cellular system;
- d) analyzing the expression of the *GABRB2* gene encoding GABA_A receptor β₂ subunit and also analysing the expression and resultant activity of the GABA_A receptor in the cellular system;
- e) determining the effect of said drugs on the expression of the GABA_A β₂ subunit and the GABA_A receptor, and the activity of the expressed GABA_A receptor in the cellular system; and,
- f) identifying drugs capable of altering the levels of expression of different forms of *GABRB2* gene containing different alleles of one or more of the six SNPs I7G1584T, rs1816071, rs1816072, rs194072, rs252944 and rs187269, and genetic markers belonging to the same haplotype or haplotypes of, or in linkage disequilibrium with, one or more of these six SNPs.

20. A diagnostic kit for detecting the identity of SNPs at positions 1584, 1803, 2103, 3106, and 3434 of intron 7, and position 1265 of intron 8 of the human *GABRB2* gene, said kit comprising components for the determination of said SNPs.

Intron 7 Base No.

TTGATAATGATGATCTCTAAAATTGCCCTTCTAGGTTCTATCCCAGGTATCCCTCAG
 CTTAACCTTAAGACAAACATTCGCTACTTTATCTGCACACATACATGCCCTCCATCCT
 GATTACCATCCTCTCTGGGTCTCCCTCTGGATTATTACGATGTTCAAGCTGCAAGGCT
 GGCAATTGGTAGGCCATTTTATTACTGCTTGTGGATTTGACTCTGTGTACATTCTG
 TGTTCGCATGCACCGCTTCTCTTATCTGAAATTGTGGTGATGACGCAACTGAACCT
 CTCACACTGTAAGAGCTTCGCTATGAGACTTGGGTGATCTGATTCAAGCATTAAATCAAT
 TAAACACGAAGTAAAGCTTCTCATGTCAGTATTGTTAACCGTATATCTGTTGATAATG
 AGATTAGTCCCATCAGTTGATATTATTGAAACATATTCAATAGTATTGCTTCA
 TAATTGTCATATTGATCTGTCTTACCTAAGAAGACCTCCCTCACGTTTTT
 TCTCCATGAAAGACAAGAGATGTTGTCAGAACATGGAAAGCAGAAAGAATTCTAA
 AGTCTGTTAACATTCAGAGTAGCATGACTAAAGCAGGAGACAACAAAGTAAGAAATT
 GAGAAGTAATCTGCGATCTCTCATCTTATGCTGTTTCTAACAAACACAAAGGA
 GAATAAAATTACATTTCATGAACATTTTGTATTAACCTCAGATAAGTAATTATGGC
 CTTTACACGATCTGATTATTGATTGACTTCTGACTATTCCCTTAAATGTTGAATTGTT
 CACTTTACATTAGATCTCAATTCAATCATTCTTAGAAGAGCCACTCATTATT
 ATTCAACAAGTAATTGTTAACATCTAATATGCTAATTGTAAGCAGTGGAGATAG
 AGCAGTCTCTGAAAGTTATCTAGCAGTAAAGATATAACATAAAATTAAATAACCACA
 TAAATTACATGTGTAATCTATAGAGGGATAAAAGCAAGGGGGCATGGTTGCT
 AGAAGTTCACTTTAGATAATTAGGGCCGACTTCACTCAGAAGTTGTCATTGAACTAAG
 ACTTGAAGATTGAGGAACTGTTGATCTGGTGTATAATTCCAGATGACTGCAAAGG
 CCCTGGTAGGAACAAACAAACAGTGTAGCAGCAGGGCTAATGGGCCAAGTGAGTTGAG
 GGGAAAGTAGCAAAGATAATTTAGGGAAAGAGGCCAAAGGATCACAAAGGGCTATTAC
 AAAGGGATGGTAGGCCACGACAACAGGCTTGCCTTATTGAAATGAAATAGCCATTGAC
 TGAGCATAAAGTGGCATGATTGTTGATCTGTTAAAGGGATCACTCGCTACTGGGT
 TAAAATTAAATTATGTCCTCAAGGATGGGAGGAAGAAATGACCTCTCAGGCTG
 AGTCAAGCACCTGTGATATACTACACTGAGTACCATAGACCTCCCTGTGTTGAGACTA
 ACCACAGTATAACTTGTGTTCTAGTGGTGTGATGTCCTTCTCAGCAATGA
 AAGATCCATGGGAAAGGTGCTCATCTAGTTATATCTGCACTGTCCTGCAATGGGAA
 TGGTCTGCAAAACATTGCTGAATGAAAGGAATAAAATTGCAATATCCCATT
 TTCCAAGTTGAAACATGCTTTGTATCATTACAGGAACATAAAATTCAATTAA
 CTTTTAGAAGACATTAAATGCTTATGTCAGCAATTATTACTAGTTGAGAAA
 TACTTTAAATGAGATTAGATAAGTAGTAAACATGCAATGTCAGTTTATATACG
 TATGATCAGGATCATCGTAGTTGAATGATGAAAGAAAATTGAAACTGGAAATGTC
 TCAAAATGACAGCTATAAAGGAGCACGAGAAATGTAAGATACTGTATCTAAAGCAAGA
 CCAAGGTTTATGGCGTCTGCAAGATCAAATGCTCAGATTATTTTTTATCTGTC
 TGGTTCTGGGAGTAAAAACAAATAGAAACTATGACATTACTACTGAGATAA
 AATTAAATCAGAAAATGTCGCCCCAAAATCATAGGAATGAAATTAAACCTTCAGGAT
 CGCTTATTGGATAGTCTTAAGGGCTGGATTCTGAGTCAGAAAGATTCTCATTC
 GGCAACTCTAACTTCCATCTGTTGATCTGACCTCTGAGCTTGTCTTTCA
 TCACTATTGCTACAAAGCTGGACTTTATCATATTCAAGGACCTGGACTTCAGTC
 TTACCTCCGATTACAGCTAGGGAAACTACTTCCACTGTCAGAGATAACCAACTCA
 ACAGGACAAACAAATTACAGCCTGACCCAGTGTACATTTCTTCAAGCAGTCAGAATG
 CATCTGTTATTATCTAGGCATTATATGCTTAATTGTCGATGCTTACATGAGGGC
 TATGATTCTGCTCTCTGTTACCCCTCACTCCAAATTCCCAGATGTTATACTATT
 TTGATGCTGTTATACTGTTAATTCTGAACTTCTGTTACCCCTGCTGTTATTGAA
 CTTCACCTCCATCATCAGTTGAGGACTCTCTGAAACCTCTTAACTGGCATTCTT
 TTTTTTTTTTTGGAGACGGACTCTGCTGCTGTCGGCCAGGGGGAGTGCAGTGGCG
 GGATCTGCTCACTGCAAGCTCCGCTCCGGTCTACGGCATTCTGCTCAGCCT
 CCCGAGTCTGGGACTACAGGGCCCGCATCACGCCCGGCTAATTGGTTATT
 AGTAGAGACAGGGTTACCGCTGTTAGCCAGGATGGTCTGATCTGACCTCGTGC
 CACCGCCCTGGCCCTCCAAAGTGTGGGATTACAAGCGTAGGCCACCGCGCCGCAA
 CTGGCATTCTTACTCTGCCATGCCCTCCCATTCACACTGTCACCAACAGT
 GATTGTTCAATGCAAATTGCCCCCTGCTGAGCTGGCCCTGCTCCACATTGCTT
 TAATTGAACTTCAACACTCCCCATTAGGCTCTGCACTGGCCCTAACCTCAGCTTC
 TCACGATTCTCCCATCTGCTTCAAGTACCCACAATGATTTCGGAGACCATGGT
 AATGGACTCTGACTCTCCCCAAATCCAACTTGTGATATAAAAGCTCTCCACAGCAG
 TCCCCATAAGTCAAAATGACTTTGACCCCCAGTGTCTGGGTTGCCCTGGGTGACTTT
 TCATCTTCTGAAATGAGCTCAAAGCTCTATTCTCTAACCTCATCCCTGGCACATCAG
 AAAGTTGACCTAGTCCTCCATATTCTGAACTCTTACCTACACATGTGCCCATCAT
 AGCATTTAACTCACGTTTACCTGGGCAACTAGATATAACTAAATACAAAAATTAA
 TAAAAAGAAGGCATCAAACCTTCAGTGTACTGTAAGCTAATTATACCTATATCCATT
 CCCTATCTAGGGCTGGCATGCAATAGTAAGGGCCAATAAAATAGATTGTCGCAATATG
 AATGAGAAAATGAATATAGATCACCTTCCAGCTATTAGAAAGAAGAAAAGAGATAGGA
 ACATTATTACTCTAACTCTCCATTCTTCTGAGGAACTCACBACTGTCCTGAGBGTGAC
 ACAATCAACACCCACCTGGGAAACTCTCCAAAATCCCTATGTGAAGGCCATTGAC
 ATGTACCTGATGGGGCTTGTCTTCTGCTTCTGCAATGGCTTCTGGAAATATGCGCTAGTC
 AACTACATCTCTTGGAGGGGGCCCCAACGCCAAAAGAAAGCAGCTGAGAAGGGCTGCC
 AGTGCACAACTGAGAAGATGCGCCCTGGATGTCACAAAGGTTAATTGAGGGCAAGGCC
 TCCCTGCTTCTTAAACTCATGGAAGAATGCTAGCAATACAGGTTGATGACCTTGTGAGC
 AAATGAGGAAACCAAGGCCAGGGAAAGGAATGGGTAATTTCCTTCCAAAGCACACAA
 TTAATGATGGAAGCACAATTAGGGACCAACTCATGACACAAGAATTGGATGCCCTTCC
 ATTAACAAAGAGGAGTGCACAAACATGAGAAGACCTTATGATGCTTCTCACATATTGAG
 TATAGTACCTATAATTATTATGATCTTAAATTATTCAACTAATTATTAAAAAG
 GAAATTAAATGTTGCTCAGTCACTTACTGTCGACAAATAGCTTACAA

Fig 1a

Intron 7 Base No.

TTGATAATGATGATGTTCTAAAATTGCCTTCTAGGTTCTATCCCAGGTATCCCCTCAG
 CTTAAAGCTTAAGAGAAAATGGCTACTTTATCTCTGGAAACATACATGCCCTCCATCCT
 GATTACCATCTCTCTGGGCTCTCTGGATTAATTACGATGCTTCAGCTGCAGGGGT
 GGCCTTAAAGTAGGGCCATTTTTAACTGCTCTGGATTGGACTCTGTGTGACATTCTG
 TGTTCGCATGCCACGCGTTTCTCTGGAAATTGTTGAGCTCTGTGTGACATTCTG
 CTCACACTGTAAGAGTTCTGCTATGAGACTTGGTGAATCTGATTCAAGCATTAAATCAAT
 TAAACACGAAGTAAAGCTCTTCATGTCAGTATTAGTTAACCGTATATCTGTTGATAATG
 AGATTAGTCCCACAGTTGATATTTTATTGAAACATATTCTATAGTATTGCTTGCA
 TAATTGTTCAATTGTTGATCTGCTCTTACCTAAGAAGACCTCCCTCACGTTTTT
 TCTCCATGAAAGACAAGAAGATGTTGAGCAAAGTAAAGCAGAAAGAATTCTAA
 AGTCTGTTAACATTCAAGAGTAGCATGACTAAGGAGGAGAACAAAGTAAGAATATT
 GAGAAGTAATCTGTCATCTCATCTTATGCTGTTTTCTAACAAACACAAAAGGA
 GAATAAAATTACATTCTATGAAACATTGTTATAACTCAGATAAAGTAATTATGGC
 CTTTTACAGATCTGATTATTGATCTGACTATTCCCTTAAATGTTGAAATTGTT
 CACTTTACATTAGATCTCAATTCAATCATTACTTCTTAGAAGAGGCCACTCATTATT
 ATTCAACAAGTAATTGTTAAATACCTAATATGTAATTGACTAAGCAGTGGAGATAG
 AGCAGTCTCTGAAAGTTATATCTAGCAGTAAAGATAACATAAAATTAAACACAA
 TAAATTACATAATGTTGAAATCTATAGAGGGATAAAAGCAAGGGCATGGGTTTGCT
 AGAAGTTCAGTTAGAATAATTAGGCCGACTTCCTCAGAAGTTGTCATTGAAACTAAG
 ACTTGAAGATTGAGAGCAATGTGGTACCTGGGTGATAATATCCAGATGACTGCAAAGG
 CCCTGGTAGGAACAAACCAACAGTCAGCAGGGCTAATGAGGCAAGTGAGTTAG
 GGGAAAGTAGCAAAGATAATGTTAGGAAAGAGGCCCTAAAGGATCACAAAAGGGCTATTAC
 AAAGGGATGGTAGGGCACAGAACAGGCTTGTCTTATTGAAATGCAATTGCTG
 TGAGCATAAAAGTGGCATGTTGATTCTGTTAAAGGGATCACTCGGCTACTGGGT
 TAAAATTAAATTGTTGCTCAAGGATGGGAGGAAGGAGAAATGACCTCTCAGGCTG
 AGTCAAGCACCTGTGATATATACACTGAGTACCCATAGACCTCCCTGTGTTAGACTA
 ACCACAGTTAACTTTGTTCTAGGGTGTATGCTTTTCCCCCTCAGCAATGAA
 AAGATCCATGGAGGAAGGTCATATCTAGTTTATATCTGCACTGTTGATGGGAA
 TGGTGCTCAGTAACATTGCTGATGAAAGAATAAAATTGCAAAATATCCCAATT
 TTCCAAGTGGAAACATGTTTTTGTATCGATACAGGAAACAATAAAATTGATTAA
 CTTTTTAAAGACATTAAATGCTTTATGTTGAGCAATTATTACTAGTTTCAAGAAA
 TACTTTAAATGAGATTGAGATAAGTAGTAAACATGCAATGTCAGTTTATTATACG
 TATGATACAGGATCATCGTAGTTGAAATGATGAGAGAAAATGAAACTGAAAATGTC
 TCAAAATGACGGCTATAAAGAGGACACGAGAAATGAAATGACTGTATCAAAGCAAGA
 CCAAGGTTTATGGGCGTCTGCAAGATCAAATGTCAGATTATTTTATTCTGTTAGC
 TGTTCTGGTGGAGTATAAAACAAAATGAGATAAGCATATTACTAGTGGAGATAA
 AATTAAATCAGAAAATCTGTCAGGCTCCAAAATCATAGGAATGAAATTAACTTCAGGAT
 GCGTTATTGGATAGTGTAAAGGGCTGGATTCTGAGTCAGAAAGATTCTCATTCCAAAT
 GGCAACTCTACAACCTTCCATCTGTTGACCTTGACCTCTGAGCTTGTCTATTTCACA
 TCACTATTGCTACAAAGCTGGACTTTATCATATTGACCTTGGACTTTCACTGCA
 TTACCTCCGATTACAGTTAGAGGAAACTACTCCACTGTCAGAGATAACCAACTCA
 ACAGGACAAACAATTACAGCCTGACCCAGTGTACATTTCATAAGCAGTCTAGAATG
 CATCTGTTATTATGAGGCTTATGCTGCTAATTGTCGATCCATATACTGAGGGC
 TATGATTCTGCTTCTGTTACCTCCACTCCTAAATTCCAGATGTTATAATCATTTA
 TTGATATTGCTGTATAATGTTATTCTTAATTGAGTACCCCTGCTGTTATTAAATTG
 CTTCACTTCCATTCAGTTGATTACTCTGAAACCTTAACTGCACTGCATTCTTTTT
 TTTTTTTTTTTTTGAGGAGGACTTGTGCTGGCCAGGGGGAGTGCAGTGGCG
 GGATCTGGCTACTGCAAGCTCCGCTCCGGGTTACGCCATTCTGCCAGCCT
 CCCGAGTAGCTGGGACTACAGGGCGCCGCCATCAGGCCGGTAATTTTTGATTTT
 AGTAGAGACAGGGTTTACCGTGTAGCCAGGATGGTCTGATCTCTGACCTCGTAC
 CACCGCCCTCGGCCCTCCAAAGTGTGGGATTACAAGCTGAGGCCACCGGCC
 CTGGCATTCTTACTCTGCGATGCCATGCTTCTCCCACATCCACACTGTCACACAGT
 GATTGTTCTAAATGCAAACTGCCCCATTGGCCCTTGCTGAAAGCTGGCCCTGCTCC
 TAATTGTTAAGTCAAACTCCCCCATTAGGCTCTGCTGATGCCCTTAACCTCCAGTC
 TCACGATTCTCCCATCTGCTTGCATGACCTTGGAGATCATGGT
 AATGGACTGTACTCTCCCCAAATCCAACTTGATATAAAACCTCTCCACAGCAG
 TCCCCATAAGTCAAAATGACTTTGACCCCCAGTCTGGGTGCTGGGTGACTTCAC
 TCATTTTCAAGAAATGAGCTCCTTCAATTCTCTAATCTCATCCCTGGACATCAG
 AAAGTTGACCTAGAGTCTCTCCATATTCTGAAACTCTACCTTACACATGTC
 AGCATTAAATTACGTTAACCCGCACTAGATATACTATATAAAACAAATTAA
 TTAAAAGAGGGATCAAAGCTGAGTCACTGTAAGCTAATTATACCTATATCCATT
 CCCTATCTTAGGGCTGGCATGCAATAGTAAAGGCCAATAAATAGATTGTC
 AATGAGAAAATGAGATATAGATCACCTTCCAGCTTAAAGAAGAAGAAAAGAGATAGGA
 ACATTATTACTCTAATCTCCATTTCAGGAAATCACAACCTGTCCTCACCATGACC
 ACAATCAACACCCACCTCGGGAAACTCTCCCTAAATCCCTATGTGAAGGGCATTGAC
 ATGACCTGATGGGTGCTTGTCTTGCATGGCCCTCTGGAAATATGCCCTAGTC
 AACATCATCTTCTGGAGGGGGCCCAAGGCCAAAAGAAGCAGCTGAGAAGGCTGCC
 AGTGCCTAACATGAGAAGATGCCCTGGATGTCAACAGGTAATTCAAGGGCAAGGCC
 TCTTGCTCTTAAACTCATGGAAGAATGCTAGCAATTACAGGTTGATGACCTTGTGAGC
 AAATGAGGAAACCAAGGCCAGGGAGAAGAATGGGTAATTTCCTCCAAACACACAA
 TTAAACAAGAGGAGTGCACAAACATGAGAAGACCTTATGATGCTTCTCACATATTGAG
 GAAATTAAATGTTGCTCAGTCACTTACTTGTGCAATAGCTTACAA

Fig 1b

Intron 8 Base No.1

ACATTATTACTCTAACCTCCCATTTCAGGAATCACAACTGTCTCACAAATGACC
 ACAATCAACACCCACCTCGGGAAACTCTCCCTAAAATCCCCTATGTGAGGCCATTGAC
 ATGTACCTGATGGGTGCTTGTCTCGTTCATGGCCCTCTGGATATGCCCTAGTC
 AACATACATCTCTGGAGGGGGCCCCAACGCCAAAGAAAGCAGCTGAGAAGGGTGC
 ACTGCCAACAACTGAGAAGTCGGCTGGATGTCACAAAGTAAATTCAAGGGTAAATT
 22. TCCTGCTTCTAAACTCATGGAAGAATGCTAGCAATACAGGTGATGACCTTGTCAGC
 82. AAATGAGGAACCAAGCCCAGGGAGAGAATGGGTAATTCTCCCAAAGCACACAACAA
 142. TTAATGATGAGAACACAATTAGGACAAACTCATGACACAAGATTGGATGCCCTTCC
 202. ATTAACAAGGGAGTGCACAAACATGAGAAGACCTTATGATGCTTCTCACATATTGAG
 262. TATAGTACCTATAATTATTATGCAATTCTAAATTCAACTAATTATTAAAAAG
 322. GAAATTAAATGTTGCTCAGTCAGTAACTTGCTGGACAAATAGCTTACAAATATATAA
 382. GTAACAAAATTAAAAACTATATCATTAAAGTTCTAAATTATACTAGATGAAAGTCCTGGC
 442. CCTGAAATCTGCATTCTGTGACTTAAAGGAAAGATAAGCAAGTATACAGATGTTAC
 502. AGACCCACCAAGCAACAACTGAGACTTTCTTGAGGACATGAGAAGAACATAAGAAG
 562. AGTAAGGGGGAAAAGACAAATAATTCTCTTAAATGACAATGCTTCACATATACC
 622. ACTTATCATTCAGCATTGACTATATGAGGCCACCATCTGCTTAAGTCAGACATGGC
 682. AAAGATTCCCACAAAACATTAACCCCTGTTATTGTAAGTCAGTAGTTTCAATCATG
 742. GGTGCAATGGAAATGACTGAAACAGATAAAAGGAAACTGAAAGCCTTGGTCCCCCCC
 802. CAGAAAATCTGATTGATTCTGGAGAAGCATGGCAACACAATTAAAAAGGTTCC
 862. CCAAGTTATTCTAATCTGCATCCAATTGAGAATCACCACTTAAAGGTTTTGATGGTA
 922. GTCCCAGTAGGCGAGCTCTTACTCTCAATTAAACTTCACCTGGCTCCTGTTAT
 982. AGCACCTGCGACTAACAGAACTTGTATATGCTTCCAGAGGCCACATTAGAC
 1042. CTTAGCAATAGCCAAAGAAAAGTCATTATTCATATCTGCCCTAAATACTGTTTATGAA
 1102. GTAGTGTCTAATATTGGACCAATAAATAGTCATCATGATGGACTAGGAAAACATTAAT
 1162. CAATCCTCTAAACCATTTGAATTATTAAATTATAACAAAGCTGATTATTCCTGATG
 1222. TTTGATATTTCAACTCAAAATTTCAGGATAGCAGAACTTAAATAATCTCTGCC
 1282. ATTGAGTTGATTGAGGCAACCATATGGAAGCTTCAACTCAGTAATGTTTACAT
 1342. ATCCATAGGTCTAATATTGTTTAAAGCTCTTCAACTCAGTAATGTTTACAT
 1402. AAGATGATATTGCAACATGCAAAATTAAAGTATGCCCTTGGAAACCAAAACCGTA
 1462. AGGGTCTAGGAATTGCAAAATTCTCCACACCCAAGGTTTACTTATTGAAATCTGC
 1522. CAATGATTCAATTACCATATTGGTCTCAGGCTGTCAAATGAAAGACTTTCT
 1582. AAACCATTTCTGATTTCATGACATAGTAGCTTAGAGAAGGAAAGGAAATAAATAA
 1642. TAAATAACACAAACAAATAATGCTATCTCATAGGACTTCAAAATGAGTCATTAATTG
 1702. ATAATGAAAGGCTGACTTAATAAGATAACATGATCTTCACCTTCATCACCTATT
 1762. TTATACCAATTGCAATTAAAGTAAAGCTTAAAGGCTAGAGGGAGGTTTATAC
 1822. AAACGACCTGCAAGGCTCAGATGTTCTAAACCGGAATAGAGAAAAGTCACTAGG
 1882. CAGTTACCCATAGTGGTAAAGCCTATCTTGGTGAAGGTAGACCTACCAATTCA
 1942. AGTGTGAAATGAGAGAACAAAAAGATACCAAGAGATTAGTATTTCAGTGGT
 2002. TCTCAAAACAGGGTCACTTCTCCCAGGGACATTAGGCATTGTCGGAGACATCTT
 2062. TCAATTAAAATAGGATGAGGTTTACTACTGGTATAGTGTGAGGGCCCAAGGT
 2122. TGCTGCTACACATTGGCAGTGTGCAGGATAGCTTCCCTGTAACCTTGTGTTTCAAACA
 2182. TGAGAAACTGAGGTACTGAAAAAAATAATCTTGTGCTAAATATTCTTAGCAAAGT
 2242. TGTCTCCATTTCAGCAGCTGTAAGAATCAAGACATCATGAGTCATGGTT
 2302. AGAACATGGTCTGAAGAACATAATTAGTCAGGCTAAGTCAATTATTCACCTCCATTAA
 2362. CAACTGGGTGACAGTAGACAAAAAATTAGCCTCTGTGGCCCTTGTAGTTTCTCATCTGT
 2422. GAAACAGGGTAATTCTCTTATAAAGTACTCATGAACATAATTGATAATGTGCA
 2482. AAGAGGGTAATAATGCTCAATACATGGTAAGCACTCAGGAAGTGTATAATTAA
 2542. AATAAATAATAAATGTTGAGGCAATTACTTAAATTAAATAATTGCACTGCCC
 2602. CATACTATTGTTGATGCTAGCGTGTGTTCTATGCTTACCATGTGGAAATGCA
 2662. GCATCCCTAARGCAGTGTATTGTTAGACAGGAATGTTTATGTTAGAAGGTTTAAAGTC
 2722. AAATCAAGAAATCATTTCAAAGGGTATTAGCTATAAAATCTATACAACTG
 2782. ATCAAACTCTATTAAATTCTTGTAGGCAAGAACCTACAACCCATTGATTAGATA
 2842. AAACAAAATGTCGACCATCAAGCTTCCAGACTCCCACATTCTTGTGACGGTCA
 2902. GAAAGGTTAGAGGGAGGTCCACATTGCTCTGATTATGCCGCTGTCTTGTGTCAGCA
 2962. TCATGAATAATACCACCCCCATTCTTATCAAGAATGTCCTCTTCAACTGTAATTCT
 3022. ATAGTTTTTTTCTCAAGATCAAGCACTTATAATCAGCTAACGATTGTTGGCTGCT
 3082. CTGGGAAAATCAGGAGTGGGATTAAATTTCACCTCTTGTGATTCTAAAGATG
 3142. GAAGGAGTGTCTGAGATTCTCAAGGTATTGACTGTGCTCTGAGGTCA
 3202. GAGGGTTGAAAACGGGAAGCTGCCAGGGAGGCCAGTGTGATTTCAGCAGATGCTA
 3262. CCCGATTTCTCAGCCTCTTGGTATTAGCGTCTCTAAATGTTGTTAAAGT
 3322. GAATTGCACTTAAATAATTCCCGTCTGTATTCTACTGACGTAAGCCTATGT
 3382. GCCTAAAGGAAGTGAAGTCACATAGCAAGCTTAAAGTCTGATATGGA
 3442. TTTTCTATCCTCTCCAGTGTACATAAAAGTGTGCTGCAAAAAAAATAA
 3502. AAAATAAAACAAACAAACAAACTGAAAGCTAACCTGTTAGTTATGTA
 3562. TTCCAACCTGAGTGTGTTCACTGAAACATCCCAGTACTGCACTGAAAGTTATAAG
 3622. CAAGTGTCACTTCACCGTTCTCATGTCAGGCTTAAGTAGTAAAGTACTAAAGATT
 3682. TAAAAATAAACTTTAACACATGAGGCTACTGAAATTTTCCAAAGTGTCTTG
 3742. GAGTAGTTAACATGATCTTATTCTAATGCTAGGAGAGTCTTCTATTCTGCT
 3802. ATTCTCTAGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGCTTAA
 3862. TGGAAATTGCTTGTGTTGATGTTCAACCTGTTCTGGCGTAGCTTCAAGTTCAACT
 3922. CCCCTACTTCTCTTAAAGCTTATATTGTTCTGTGTTTCTGCAAAATACTA
 3982. AGAACACCCATATTGAGAATCAAGTATTCTGCTTACCCACCGTGGTATTGCA
 4042. ATATCAAAATGCACTGCAAGCCACAGCTTCTAACTAAAGCTGCAACACAGAGATCTCA
 4102. TTAAGGGTGTCTTATTCTGCAATTGCTGACTCTTGTGTTGTTGCTTAA
 4162. CATTGTGTAATCTTCTAATGAAAGCAGTAAAGATATTTCACATCAATTATTCT
 4222. ACTGCTGGAATTGATGTTTAAACAAAATTTTAAAGACTTACTCAAAATTCCC
 4282. ATTCTCTGTTAGGCTTATCTAAAGGATTCTAAAGGCCAGTAGCATTATCTATATCCA
 4342. ATTACTTAAACACGCGCTTACAGGCTAACTGAGCATCAATGCACTTAATTAGCACATTCTC
 4402. TACTTGTCTCCAGATTTTATAAGATAATTAAACAAAGGGACCAATTATCGATCC
 TTGAGGACCCACTGGAAACCTCTCCCAACTAGACGGACTGCCATTACGATTTCT
 CTGATACGGTTAGATAGGCCAGTTTTAATCCTATTGTTGTTGGGGCAAT




Fig 3




Fig 4

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2004/000287

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12Q 1/68 C07H 21/04 A61P 25/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C12Q C07H A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

IPC7: C12N 15/00

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, EPODOC, PAJ, CA, MEDLINE, CPRS, CNKI: single nucleotide polymorphism, SNP, schizophrenia

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2003008301 A , LANDER E S et al , 9 Jan 2003 (2003-01-09) page 1-2; claims 1-24	5-20
A	WO 03020911 A , DECODE GENETICS EHF , 13 Mar 2003 (2003-03-13) page 3, line 28-page 4, line 31; claims 13, 19,33,41	5-20
A	WO 02075317 A , NOVARTIS AG et al , 26 Sep 2002 (2002-09-26) page 2, line 8-page 4, line 13; claims 7,26	5-20

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim (S) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
20 Jun 2004 (20.06.2004)

Date of mailing of the international search report

01 • JUL 2004 (01 • 07 • 2004)

Name and mailing address of the ISA/

China State Intellectual Property Office (RO/CN)
6,Xitucheng Road, Jimen Bridge, Haidian District,
Beijing, 100088, P.R.China
Facsimile No. (86-10)62019451

Authorized officer



Telephone No. (86-10)62085288

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2004/000287

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Hui Liu et al: "Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia." Proc-Natl-Acad-Sci-U-S-A., Vol.99, No.6, 19 March 2002 (2002-03-19), pages 3717-3722 the whole document	5-20
A	LIU Lin-lin et al: "Relationship Between the NOTCH ₄ Locus of Chromosome 6 and Schizophrenia" Journal of Jilin University (Medicine Edition), Vol.29, No.1, 20 Jan 2003 (2003-01-20), pages 29-31 the whole document	5-20